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Abstract
Mutations in multiple genes of the growth hormone/IGF-I axis
have been identified in syndromes marked by growth failure.
However, no pathogenic human mutations have been reported in
the six high-affinity IGF-binding proteins (IGFBPs) or their regula-
tors, such as the metalloproteinase pregnancy-associated plasma
protein A2 (PAPP-A2) that is hypothesized to increase IGF-I bioac-
tivity by specific proteolytic cleavage of IGFBP-3 and -5. Multiple
members of two unrelated families presented with progressive
growth failure, moderate microcephaly, thin long bones, mildly
decreased bone density and elevated circulating total IGF-I, IGFBP-3,
and -5, acid labile subunit, and IGF-II concentrations. Two different
homozygous mutations in PAPPA2, p.D643fs25* and p.Ala1033Val,
were associated with this novel syndrome of growth failure. In
vitro analysis of IGFBP cleavage demonstrated that both mutations
cause a complete absence of PAPP-A2 proteolytic activity. Size-
exclusion chromatography showed a significant increase in IGF-I
bound in its ternary complex. Free IGF-I concentrations were
decreased. These patients provide important insights into the
regulation of longitudinal growth in humans, documenting the
critical role of PAPP-A2 in releasing IGF-I from its BPs.
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Introduction
The growth hormone (GH)/insulin-like growth factor (IGF)-I system
is essential for optimal human growth. GH promotes growth via
IGF-I production and by direct actions on the growth plate. IGF-I
circulates bound to six IGF-binding proteins (IGFBPs). After binding
IGF, IGFBP-3, and -5 also bind with the IGF acid labile subunit
(ALS) to form a ternary complex, which further increases IGF-I’s
half-life (Baxter, 2000). Free IGF-I (fIGF-I) binds its receptor, activat-
ing signaling cascades that up-regulate multiple genes fundamental
to growth (Yakar et al, 2002). Human genetic defects in this axis
lead to syndromes marked by impaired growth and have helped to
further our understanding of growth physiology (David et al, 2011).
GH receptor (GHR) mutations were shown to cause Laron syndrome
with extreme growth failure (Amselem et al, 1989). Mutations in
the STAT5B (Kofoed et al, 2003), IGF-I (Woods et al, 1996) and
IGF-I receptor (IGF-IR) (Abuzzahab et al, 2003) genes cause varying
degrees of pre- and postnatal growth retardation and mutations in
ALS cause mild short stature (Domene et al, 2004). The first
mutation in IGF2 affecting pre- and postnatal growth was recently
identified (Begemann et al, 2015). To date, no human mutations in
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the six high-affinity IGFBPs or their regulatory proteins have been
reported in association with a monogenic syndrome. We present
two families with homozygous loss-of-function mutations in
PAPPA2, a gene encoding pregnancy-associated plasma protein-A2
(PAPP-A2), a protease highly specific for IGFBP-3 and -5 (Overgaard
et al, 2001), resulting in a novel syndrome of growth retardation
with markedly elevated circulating IGF-I and IGF-II, but decreased
fIGF-I concentrations and IGF bioactivity.
Results
Patient descriptions
Family one consists of four children of Spanish ancestry born to
parents with no known consanguinity. Subject II.1 was evaluated at
nine years of age for short stature with a height 1.7 SDS below her
mid-parental target height (50th–75th percentile) and elevated serum
IGF-I, ALS, and IGFBP-3 concentrations (Table 1). Spontaneous GH
secretion over eight hours (daytime) was elevated (4.8 ng/ml/8 h;
normal 2.8–3.3). Her younger brother’s height (Subject ll.3) was 1.3
SDS below mid-parental target height, with similar elevations in
IGF-I, IGFBP-3, and ALS (Table 1) and spontaneous GH secretion
(5.3 ng/ml/8 h). Their birth lengths and weights were normal,
although smaller than their unaffected sisters (II.2 and II.4;
Table 1). Subject II.3 was born premature, but was adequate for
gestational age, with a normal catch-up growth (Fig 1B). Their
growth patterns revealed consistent short stature relative to target
height, with more prominent growth deceleration as they age (Fig 1,
Appendix Fig S1). Subtle dysmorphic features consist of small chins,
mild microcephaly (1.37 & 1.65 SDS at birth; 2.03 & 2.19 SDS
at first physical examination), and long fingers and toes (Fig 1A
and B). They are prepubertal. Glycemia was normal on oral glucose
tolerance tests, but with mild fasting hyperinsulinemia (15.1 and
27 lU/ml, normal 4–13). The unaffected sisters were within 1 SDS
of their mid-parental target height with normal IGF-I serum concen-
trations (Table 1, Appendix Fig S2).
Family two consists of five children of Palestinian ancestry born
to parents of normal stature (mid-parental target height 30th percen-
tile) who are first cousins. Siblings II.3, II.4, and II.5 had significant
postnatal growth retardation with high serum IGF-I and IGFBP-3
concentrations. When Subject II.3 was evaluated for short stature at
age 6.8 years of age, her height was 3.5 SDS below her target
height and IGF-I was 517 ng/ml (normal 47–217). An elevated
IGFBP-3 level of 6,400 ng/ml (normal 2,100–4,200) was found later.
She showed peak GH concentrations > 50 ng/ml on both clonidine
and arginine tests. Her growth chart demonstrates progressive
growth failure, no discernible pubertal growth spurt and a final
adult height of 138.4 cm (3.81 SDS; Fig 1C). She had normal
pubertal timing, undergoing menarche at age 13.8 years of age, and
had elevated IGF-I throughout childhood (Appendix Table S1; most
recent value 1,060 ng/ml at age 18 years). Two younger brothers
also had progressive growth failure (Fig 1D and E). Subject II.4 was
evaluated for growth failure at age 12.5 years of age with an IGF-I
level of 657 ng/ml (normal 93–567) despite being prepubertal.
Subject II.5 was evaluated at 8.3 years of age with an IGF-I level
of 636 ng/ml (normal 49–351). Their peak GH concentrations
after stimulation testing with clonidine and L-Dopa were 14.7 and
37 ng/ml, respectively. Fasting glucose concentrations were normal
in both brothers, with mild hyperinsulinemia in Subject II.4
(17.1 lU/ml) and a normal insulin level of 7 lU/ml in Subject II.5.
Subjects II.3 and II.4 were born mildly small for gestational age, but
Subject II.5 was within the normal range (Table 1). All three
affected siblings had long thin fingers, a small chin, moderate micro-
cephaly (Table 1) and delayed dental eruption.
Skeletal surveys in the two affected siblings from family one and
subjects II.4 and II.5 in family two showed no signs of overt skeletal
dysplasia; however, thin long bones most prominent in the fibulae,
tibiae, and femurs were found (Fig 1F). Bone age was consistent
with chronologic age in all subjects.
DXA scans (QDR 4500, Hologic, Waltham, MA) were performed
on the two affected siblings from family one. Bone mineral density
was decreased at the lumbar spine (height adjusted Z-score 2.49
SDS in II.1, 2.0 SDS in II.3).
Micro-CT analysis of a tooth extracted from Subject II.1 in family
one showed significantly decreased enamel and dentin density
(Fig EV1). No significant cognitive dysfunction or hearing abnor-
malities were found in the patients from either family.
Genetic analysis
Given the two affected siblings of different sex in family one with
unaffected parents, we hypothesized that the disorder had an auto-
somal recessive inheritance pattern. After excluding mutations in
the IGF-IR gene, whole-exome sequencing was performed in the
affected sister (II.1). We searched for genes with either a single
homozygous or two heterozygous rare (minor allele frequency
< 1%) nonsynonymous variants present. Five genes met these
criteria (Appendix Table S2), four of which fell within a block of
homozygosity on chromosome one, suggesting that the parents have
a distant common ancestor. The novel homozygous frameshift
mutation in PAPPA2 (c.1927_1928insAT, p.D643fs25*) was high-
lighted as the likely causal variant, given the loss-of-function nature
of the mutation and the role of the encoded protein, PAPP-A2, in
cleaving IGFBPs. This variant was confirmed via Sanger sequencing
to be homozygous in both affected individuals, heterozygous in
both parents and one unaffected sibling (II.4), and absent in the
second unaffected sibling (II.2) (Fig 2).
Due to the known consanguinity in family two, we assumed that
the affected children were homozygous carriers of a rare autosomal
recessive variant causal for their growth retardation. Genome-wide
genotyping performed in the three affected children identified
four large (> 6 MB) shared regions of homozygosity (Appendix
Table S3). Whole-exome sequencing was performed on Patient II.3.
Analysis focused on rare homozygous nonsynonymous variants
within the shared regions of homozygosity. Two novel missense
variants met these criteria, only one of which segregated in the
family (Fig 2): a novel missense variant in PAPPA2 (c.3098C > T,
p.Ala1033Val).
Neither of the two PAPPA2 variants was found in public data-
bases representing more than 60,000 exomes and including at least
700 individuals from Spain. Notably, there are no individuals in
these large datasets with homozygous loss-of-function variants of
the PAPPA2 gene. Thus, the genetic analyses of these two families
identified two novel nonsynonymous mutations in PAPPA2 as the
likely causal variants.
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In vitro functional effects of mutations in PAPPA2
PAPP-A2 is a metalloproteinase that specifically cleaves IGFBP-3
and -5 (Overgaard et al, 2001). To assess the consequences of
our subjects’ mutations on PAPP-A2 proteolytic function, recom-
binant variants were compared with wild-type (WT) PAPP-A2
following transfection of HEK 293 cells. Media from cells trans-
fected with cDNA encoding the D643fs or A1033V variants
showed no proteolytic activity toward IGFBP-3 or -5 under
conditions where media from cells transfected with WT PAPP-A2
cDNA completely cleaved these substrates (Fig 3A). As expected,
none of the variants cleaved the PAPP-A substrate, IGFBP-4.
Western blotting showed a complete lack of expression for the
D643fs mutant (as would be expected with a severely truncated
protein), while expression of A1033V was markedly reduced
compared to WT PAPP-A2. Upon reduction of disulfide bonds,
two bands appeared for A1033V, probably caused by partial
intramolecular cleavage (Fig 3B). To further analyze the A1033V
mutant, samples were adjusted for the reduced expression of this
variant and, at equimolar concentrations (Fig 3C), it still showed
no activity, suggesting that neither full-length A1033V nor proteo-
lytically cleaved A1033V is capable of cleaving the IGFBPs.
Table 1. Anthropometric and biochemical data.
Subject ID Sex
Gestational
age (weeks)
Birth weight
(kg)
Birth length
(cm)
Age at examination
(years) Height (cm) BMI (kg/m2) HC (SDS)
Family 1
II.1 F 37 2.19 (1.49) 48.0 (0.07) 10.3 132.2 (1.10) 13.9 (1.52) 2.03
II.2 F 39 3.35 (0.44) 51.0 (0.94) 7.8 129 (0.87) 14.8 (0.98) +0.02
II.3 M 35 1.99 (1.27) 45.0 (0.55) 5.7 110.4 (0.96) 13.4 (2.03) 2.19
II.4 F 40 3.64 (0.96) 50.0 (0.11) 3.6 103.3 (1.62) 15.6 (0.44) 0.98
Family 2
II.1 F 40 3.26 (0.61) 48.3 (1.30) 22.2 149.3 (2.16) 24.9 (0.76) 0.45
II.2 F 40 3.57 (0.01) 48.3 (1.30) 19.8 153.9 (1.45) 21.7 (0.01) 1.06
II.3 F 41 2.58 (2.16) 45.7 (2.75) 18.6 138.4 (381) 20.9 (019) 2.03
II.4a M 41 2.84 (1.69) 47.0 (2.18) 13.8 139.1 (2.82) 26.7 (1.61) 1.60
II.5 M 39.4 2.82 (1.28) 48.5 (0.94) 9.5 117.7 (3.14) 15.4 (0.65) 1.08
Total IGF-I
(lg/l)
Total IGF-II
(lg/l)
Bioactive
IGF (lg/l)
Free IGF-I
(lg/l)
BioIGF/Total
IGF-I (%)
IGFBP-3
(lg/l)
IGFBP-5
(lg/l)
ALS
(U/L)
PAPP-A2
(lg/l)
Family 1
II.1 957 1,198 0.87 1.39 0.09 5,912 997 3,745 NDb
II.2 340 850 2.30 2.08 0.68 3,696 457 2,588 0.13
II.3 882 1,264 1.54 0.27 0.17 4,850 853 3,625 NDb
II.4 264 759 3.21 2.16 1.22 3,384 322 2,206 0.25
Family 2
II.1 237 763 2.31 4.34 0.97 3,235 179 1,375 0.34
II.2 490 629 3.90 8.36 0.80 3,007 187 1,412 0.44
II.3a 1,060 921 3.35 1.98 0.32 4,557 760 2,445 0.23
II.4c 935 914 2.70 3.31 0.29 4,792 981 2,959 0.42
II.5 831 946 0.98 0.35 0.12 4,403 645 2,456 0.30
Normal Values
Tanner I 91–225 495–911 dPrepubertal
1.94  0.15
1.58–3.15
emedian 1.23%
(range 0.46–2.59%)
2,206–4,200 211–707 753–2,634 0.16–2.69
Tanner V 270–617 560–794 dPubertal
2.93  0.15
4.89–9.37 2,796–5,280 293–1,023 1,260–4,030 0.23–0.80
Affected individuals are shaded in light gray. Unaffected individuals are not shaded. Values in parentheses indicate the standard deviation score (SDS) for
anthropometric measures.
aThis subject is an adult.
bZero values in the affected patients are expected because of the frameshift mutation resulting in the absence of the target epitopes of the assay. HC: head
circumference. BioIGF: Biologically active IGF.
cThis subject was Tanner stage 2 at the time of examination and biochemical evaluation with 5-6 cc testes. ND: not detectable.
dNormal ranges for bioactive IGF are based on Sorensen et al (2015).
eThe normal ratio of bioactive IGF to total IGF-I is based on 95 healthy subjects aged 7–25 years. The ratio was not associated with age.
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In vivo evaluation of IGF-I and IGFBPs
To further delineate the in vivo consequences of our subjects’ muta-
tions on IGF-I physiology, we measured serum PAPP-A2 concentra-
tions. As expected, subjects in family one homozygous for the
D463fs truncating mutation had no detectable PAPP-A2 (Table 1).
In family two, PAPP-A2 concentrations were detectable at the low
end of the normal range, but with no difference between the affected
individuals and their heterozygous siblings.
Serum concentrations of total IGF-I were elevated above the
normal range in all affected subjects and normal in their unaffected
siblings (Table 1). IGFBP-3 concentrations were above the normal
range in the four younger patients and in the upper normal range in
the Tanner V subject of family two. ALS concentrations were
elevated in three of five subjects and in the upper limits of normal
in two. Serum IGFBP-5 concentrations were elevated in four of five
patients. IGF-II concentrations were elevated in all five patients
(Table 1). As PAPP-A2 cleaves IGFBP-3 and -5 thereby releasing
IGF-I from the ternary complex, we hypothesized that fIGF-I concen-
trations would be decreased in the affected subjects, despite the
elevated total IGF-I concentrations. Indeed, fIGF-I concentrations
were low in four of five patients (Table 1), suggesting that they
have a functional defect in the ability to liberate IGF-I from its bind-
ing partners. To substantiate this finding by an independent
A B C
D E F
Figure 1. Growth charts and photographs of affected subjects.
A Family 1, Subject II.1.
B Family 1, Subject II.3.
C Family 2, Subject II.3.
D Family 2, Subject II.4.
E Family 2, Subject II.5.
F Top Row—Representative X-rays showing narrow fibulae and elongated digits in Subject II.1 of Family 1. Bottom Row—Lower extremities and foot from Subject II.5
and hand from Subject II.4, both from Family 2.
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method, the potential of the patients’ serum to stimulate the IGF-IR
in vitro was assessed. IGF bioactivity was lower in the three prepu-
bertal patients compared to unaffected prepubertal subjects, with
the percentage of bioactive IGF (bioactive IGF/total IGF-I) reduced
in all affected patients (Table 1).
To further confirm that defects in PAPP-A2 function can cause
this unique phenotype, we demonstrated that mice carrying a
targeted deletion of Pappa2 (Conover et al, 2011) also have mark-
edly decreased fIGF-I concentrations, despite a > 50% increase in
total IGF-I concentrations (Appendix Table S4).
Lastly, measurement of the amount of IGF-I bound in ternary
complexes in the serum of subjects of family one showed a marked
increase in IGF-I as part of the ternary complex in all affected
subjects (Fig 4A). Moreover, in these patients, the overall capacity
to form ternary complexes was greatly increased compared to
prepubertal controls (Fig EV2A and B).
Discussion
We present two families with a novel syndrome of progressive
growth failure with markedly elevated serum concentrations of
IGF-I, IGFBP-3 and -5 resulting from loss of PAPP-A2 function.
PAPP-A2, a member of the pappalysin family of metzincin metallo-
proteinases, is closely related to PAPP-A, a protease that targets
IGFBP-4 (Oxvig, 2015). While PAPP-A has been extensively studied
due to its biomarker roles (Bayes-Genis et al, 2001; Malone et al,
2005), the function of PAPP-A2 in human physiology is largely
unknown. Prior in vitro work has shown that PAPP-A2 specifically
cleaves IGFBP-3 and -5 with no activity toward other IGFBPs
(Overgaard et al, 2001). We demonstrate that loss of PAPP-A2 function
leads to increased serum concentrations of IGFBP-3 and -5 resulting
in increased total IGF-I concentrations. Total IGF-II is also elevated,
consistent with the increased ALS and IGFBP-3 concentrations.
mRNA
Signal hctoNhctoN3_G_ninimaL
Peptidase_M43
SushiFibronectin_t3
2 3 4 5 7 8 9 10 11 12 13 14 1615 17 18 19 20 231 21 226
ATG TAA
Prot
* *
**
c.1927_1928insAT 
p.D643fs25X
c.3098C>T
p.A1033V
Fam1
1 2
1 2 3 4
I
II
I1: p.D643fs (het)
(wt)
1032D  A/V A    L 1032D   V A     L
1032D   A A     L
**
642 G    D C    C
II1: p.D643fs (hom)
642 G   D fs  T A642 G   D fsT/C A/C
(wt)
I1: p.A1033V (het) II3: p.A1033V (hom)
A
B C
G G A G A T A C T G C T
C T G C T G C
G G A G A T A C T G C T
G G A G A C T G C T G C
Fam2
1 2
1 2 3 4 5
I
II
Figure 2. PAPPA2 gene and family pedigrees.
A Schematic representation of the genomic structure of the PAPPA2 gene on chromosome band 1q24, the encoded mRNA and the protein with its relevant functional
domains. Red stars indicate the location in the exons, mRNA and protein where the subjects’ mutations are found.
B Pedigree and representative Sanger sequencing trace of the mutation identified in family 1.
C Pedigree and representative Sanger sequencing trace of the mutation identified in family 2.
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However, this increase in total IGFs was not accompanied by an
elevated ability of serum to activate IGF-IR in vitro (IGF bioactivity).
We hypothesize that this relative decrease in IGF bioactivity is due
to an inability of the abnormal or deficient PAPP-A2 to liberate IGF-I
from its binding partners resulting in decreased fIGF-I. The primary
site of action for PAPP-A2 is unknown. Unlike PAPP-A, PAPP-A2 is
not membrane bound and does not require the presence of IGF-I for
its proteolytic function (Overgaard et al, 2001). We do not know
whether the growth failure is due to a systemic effect or a defect in
PAPP-A2 function at the tissue level, in particular at the growth
plate. It is also possible that aspects of the patients’ phenotype could
be due to direct effects of the increased IGFBPs. Interestingly, GH is
elevated in the patients, resulting in increased concentrations of all
GH-dependent factors (IGF-I, IGFBP-3, IGFBP-5, and ALS). We
hypothesize that the rise in GH is due to decreased negative feed-
back consequent to low fIGF-I concentrations (Fig 4B). Thus, our
study indicates that PAPP-A2 is a key regulator of human growth
and IGF-I bioavailability by regulating the proportion of IGF-I that is
either free or bound to its IGFBPs.
Mouse models of PAPP-A2 deficiency have striking similarities to
our patients, as Pappa2/ mice recapitulate the human biochemi-
cal phenotype with elevated total IGF-I and low fIGF-I concentra-
tions. Pappa2/ mice exhibit a trend toward decreased birth
weight and significant postnatal growth retardation (Conover et al,
2011; Christians et al, 2013), which correlates with our findings as
the patients were born mildly small for gestational age and exhibited
the most prominent growth failure postnatally. Indeed, progressive
postnatal growth retardation occurred in all affected individuals,
becoming more prominent with age. While the range in the absolute
heights of the affected patients is wide, subjects in family one are
quite discordant from their target mid-parental height and it is yet to
be seen if their growth failure becomes progressively worse with
age, as seen in family two. PAPP-A2 is responsible for the proteoly-
sis of IGFBP-5 during pregnancy resulting in increased fIGF-I (Yan
et al, 2010), but how this affects fetal growth and development in
normal individuals and in our subjects is unknown. Lack of PAPP-
A2 led to decreased length of the mandible, skull, femur, pelvic
girdle, and tailbone in mice (Christians et al, 2013) and severely
reduced cranial cartilages in zebrafish (Kjaer-Sorensen et al, 2014).
Our subjects had small chins, long thin fingers, thin femurs and
moderate microcephaly. In the two subjects undergoing DXA, one
showed mild osteoporosis and the other osteopenia. Mice
with blunted IGF-I activity in osteoblasts show defects in bone
mineralization during postnatal growth (Zhang et al, 2002). Trans-
genic mice overexpressing IGFBP-3 (Modric et al, 2001) have
A
B
C
Figure 3. In vitro characterization of mutated PAPP-A2.
A Assessment of proteolytic activity present in culture media of human
embryonic kidney 293T cells transfected with cDNA encoding PAPP-A2,
PAPP-A2(D643fs) (family 1), or PAPP-A2(A1033V) (family 2). Radiolabeled
substrates tested include IGFBP-3, IGFBP-4, and IGFBP-5. Cleavage was
visualized by autoradiography following SDS–PAGE. Positions of intact
IGFBPs (i) and cleavage products (c) are indicated.
B Western blots following nonreducing or reducing SDS–PAGE of media from
transfected cells, as indicated. Polyclonal antibodies raised against the
N-terminal portion of PAPP-A2 were used for detection.
C Comparison of proteolytic activity similar to the experiment of panel (A),
except that equimolar concentrations of PAPP-A2 and PAPP-A2(A1033V)
were used. The variant from Family 1, carrying a frameshift mutation
N-terminal to the proteolytic domain of PAPP-A2, did not show any
detectable expression. All gels and blots are representative of three
independent experiments.
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AB
Feedback
IGF-INo PAPP-A2 activity
X
↓↓↓fIGF-I
IGFBP-3↑↑↑
ALS↑↑↑
IGF-I↑↑↑
↑↑
Binding to 
IGF receptor ↓
↑↑Ternary complexIGFBP-5↑↑↑
GH
GH
↓
IGF-II↑↑↑
II.1
II.2
II.3
II.4
controlPrepubertal
Figure 4. IGF-I neutral chromatography and proposed mechanism of action of PAPP-A2 deficiency.
A Concentrations of endogenous IGF-I in the different fractions obtained by neutral chromatography on a Superdex 200 column. Serum samples from the four siblings
of family 1 were analyzed and compared to a nonrelated prepubertal control, as all siblings were prepubertal. The amount of IGF-I detected in the fractions
corresponding to the ternary complex (TC) was markedly greater in the homozygous affected subjects (II.1 and II.3) compared to the unaffected siblings (II.2 and II.4)
and the prepubertal control. No IGF-I was detected in the fractions corresponding to the binary complex (BC) or fIGF-I in any of the subjects. This is most likely due to
the fact that under physiological conditions 80-85% of IGF-I circulates in the TC and after the separation procedure, the amount of IGF-I in the BC or free was below
the level of detection of our IGF-I assay. These results clearly demonstrate that in the affected patients the amount of IGF-I circulating in the TC is markedly elevated.
B Cartoon of hypothesized mechanism underlying growth failure due to lack of PAPP-A2. There is an increase in the formation of ternary complexes, due to decreased
proteolysis subsequent to the lack of PAPP-A2 activity. This results in reduced concentrations of fIGF-I in serum and most likely at specific target tissues. This also
decreases the negative feedback effect of IGF-I on growth hormone (GH) production, contributing to the increased circulating concentrations of GH. Increased serum
GH concentrations cause increased IGF-I, IGFBP-3, and ALS concentrations. This increase in IGFBP-3 and ALS would then contribute to further ternary complex
formation and an increase in total IGF-I and IGF-II concentrations.
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modest pre- and postnatal growth retardation despite high IGF-I
concentrations, presumably reflecting reduced fIGF-I, as seen in our
patients. The mild fasting hyperinsulinemia in three of five patients
is possibly due to the elevated GH concentrations.
The gene encoding PAPP-A2 was located in a quantitative trait
locus for body size in mice (Christians et al, 2006) and PAPP-A2
was confirmed to be partially responsible for the effect of this locus
(Christians et al, 2013). A SNP located in close proximity to human
PAPPA2 (rs1325596) was recently identified in a large genome-wide
association study as being correlated with height in the general
population (Lango Allen et al, 2010; Wood et al, 2014). Thus,
common genetic variants in PAPPA2 may have mild effects on
growth, while rare loss-of-function variants, such as those seen in
our subjects, have a more pronounced effect.
In conclusion, we have identified a new syndrome in two unre-
lated families with loss-of-function variants in PAPPA2 resulting in
progressive growth failure, moderate microcephaly, thin long bones,
a marked elevation of total IGF-I concentrations due to impaired
proteolysis of IGFBP-3 and -5, and reduced fIGF-I. These patients
represent the first human cases of diminished IGF-I bioavailability
due to defects in IGFBP regulation, indicating that PAPP-A2 is a key
regulator of IGF-I bioavailability and that deregulated IGFBP proteol-
ysis can have relevant consequences in human physiology.
It remains to be seen whether postnatal growth in these children
can be improved. One potential treatment includes human recombi-
nant IGF-I. It is possible that increasing total IGF-I in the circulation
could shift the equilibrium of the GH-IGF system such that there is
also an increase in free/bioactive IGF-I, which could result in
increased systemic growth. This hypothesis is now being tested as
the prepubertal patients are under hrIGF-I therapy.
The results reported here also emphasize the potential impor-
tance of proteins that interact with PAPP-A2 (Kloverpris et al, 2013)
that have been previously shown to affect human height (Lango
Allen et al, 2010). Thus, patients currently labeled as idiopathic
short stature with elevated IGF-I and IGFBP-3 concentrations could
conceivably obtain a specific diagnosis after undergoing testing for
mutations in PAPPA2, or possibly in proteins that regulate the activ-
ity of this protease. Indeed, the data presented here indicate that
understanding PAPP-A2 regulation and function will have important
implications in both the clinical diagnosis of growth retardation and
other areas of IGF-I biology.
Materials and Methods
Studies were approved by the Institutional Review Boards at the
Hospital Infantil Universitario Nin˜o Jesu´s and Cincinnati Children’s
Hospital Medical Center. Written informed consent was obtained
from all subjects or their legal guardians and the experiments
conformed to the principles set out in the WMA Declaration of
Helsinki and the Department of Health and Human Services
Belmont Report. Full consent was also obtained for the publication
of the patients’ pictures.
Genetic analysis
In family two, homozygosity mapping analysis was implemented
on genome-wide SNP data using PLINK (Purcell et al, 2007).
Whole-exome sequencing was performed in the probands of both
families at each institution as previously described (Argente et al,
2014; de Bruin et al, 2015).
Serum assays
ELISAs were used to measure serum concentrations of acid labile
subunit (ALS; Mediagnost, Reutlingen, Germany), IGF-I, free IGF-I,
IGFBP-3, IGFBP-5, and PAPP-A2 (Ansh Labs, Webster, TX, USA).
All assays were performed according to the manufacturers’ instruc-
tions. Briefly, in all determinations, after incubation of the serum
samples in a microtiter plate previously coated with the correspond-
ing antibody, the wells were washed and the enzyme conjugate was
added. At the end of the incubation period and after washing, a
substrate solution was added until the color developed adequately.
Measurements were taken at 450 nm with an automatic microplate
analyzer.
The PAPP-A2 ELISA employed is a two-site assay based on speci-
fic monoclonal antibodies. Epitope mapping of the two antibodies
has been published earlier (Kloverpris et al, 2013). The catching
antibody maps to the SCR3 module and the detecting antibody maps
to the SCR1 module of PAPP-A2. All SCR modules are located
C-terminal to the site of mutations.
Serum insulin concentrations were measured by an immunora-
diometric assay from DIAsource ImmunoAssays (Louvain-la-Neuve,
Belgium). Samples were dispensed, and a 125I-anti-insulin
monoclonal antibody was added into the tubes coated with another
anti-insulin monoclonal antibody. After incubation and washing,
the bound fraction was counted in a gamma-counter.
In all assays, the intra- and inter-assay coefficients of variation
were lower than 10%. Normal ranges were obtained by measuring
concentrations in groups of Tanner Stage I or V healthy controls
recruited from the clinic at the Hospital Infantil Universitario Nin˜o
Jesu´s (n = 50 in each group).
Bioactive IGF concentrations were measured by kinase receptor
activation assay (KIRA) as previously described (Chen et al, 2003;
Reinhard et al, 2013). Briefly, this assay measures the ability of IGF
in serum to phosphorylate the IGF-I receptor (IGF-IR) in an in vitro-
based model employing human embryonic cells transfected with
cDNA of the human IGFR gene. The ability of serum to phosphory-
late the IGF-IR in vitro is compared to a serial dilution of IGF-I. This
assay also detects IGF-II and pro-IGF-II activation of the IGF-IR
(cross-reactivity 12% and 2%, respectively), but the cross-reactivity
of proinsulin and insulin is negligible (< 1%). Thus, the output of
this assay is referred to as IGF bioactivity as both IGF-I and IGF-II
can activate the IGF-IR. The detection limit of this assay is
< 0.08 lg/l.
Chromatography for endogenous IGF-I complex profiles
Levels of complex-bound endogenous IGF-I were assayed by neutral
size-exclusion chromatography and the capacity to form such
complexes as previously described (Domene et al, 2004). Briefly, to
determine the IGF-I complex profile, we performed neutral chro-
matography of 300 ll of serum on Superdex 200. Two-ml fractions
were collected and those corresponding to the ternary (six frac-
tions), binary (seven fractions) and free IGF-I (one fraction) were
collected and dried in a speed vacuum, reconstituted in 100 ll of
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PBS buffer 0.05 M, NaCl 0.15 M, pH 7.4, BSA 0.5%, and IGF-I was
extracted by alcohol-acid treatment and cryoprecipitation. The IGF-I
concentration in each fraction was then determined by QLIA (Immu-
lite, Siemens) according the manufacturer’s instructions.
Mutagenesis
Recombinant PAPP-A2 and variants thereof were generated by
transfection of mammalian cells with WT or mutated cDNAs.
Mutated proteins were compared to WT PAPP-A2 in their abilities to
proteolytically cleave radiolabeled IGFBP-3, -4, and -5 and by
Western blotting following nonreducing or reducing SDS–PAGE.
Plasmid constructs encoding variants of human PAPP-A2 were
made by overlap extension PCR (Ho et al, 1989) using human
PAPPA2 cDNA contained in plasmid pPA2 (Overgaard et al, 2001)
as a template. Outer primers were 50-CTGTATGTGGATGGCACTC
AGG-30 and 50-GCAACTAGAAGGCACAGTCGAG-30. Overlapping
mutated sets of internal primers were 50-CTTTGACGACGGAGAT
ACTGCTG-30 and 50-CAGCAGTATCTCCGTCGTCAAAG-30 for mutant
PAPP-A2(D643fs), and 50-GAGGATAGAGATTGATGTAGCACTCCTG
ACTTCTC-30 and 50-GAGAAGTCAGGAGTGCTACATCAATCTCTATC
CTC-30 for mutant PAPP-A2(A1033V). The mutated fragments were
digested with XbaI and XhoI and swapped into pPA2 to generate
plasmids pPA2(D643fs) and pPA2(A1033V), respectively. Plasmid
DNA was prepared by GenElute HP Plasmid Miniprep Kit (Sigma).
All constructs were verified by sequence analysis.
Cell culture and transfection
Human embryonic kidney 293T cells (293tsA1609neo, ATCC CRL-
3216) (Pear et al, 1993) were maintained in high-glucose DMEM
supplemented with 10% fetal bovine serum, 2 mM glutamine,
nonessential amino acids, and gentamicin (Invitrogen). The cells are
routinely tested for mycoplasma contamination. For transient trans-
fection, 6.0 × 106 cells were plated onto 10-cm dishes and trans-
fected 18 h later by calcium phosphate coprecipitation using 10 lg
plasmid DNA (Overgaard et al, 2000). In addition to plasmid
constructs encoding PAPP-A2 or mutated variants, constructs
encoding human IGFBP-3 (Laursen & Oxvig, 2005), human IGFBP-4
(Boldt et al, 2001), or human IGFBP-5 (Overgaard et al, 2001) were
used. Culture supernatants were harvested 48 h post-transfection
and cleared by centrifugation, or the cells were further cultured in
serum-free medium (CD293, Invitrogen) to facilitate purification of
the secreted proteins. Concentrations of WT PAPP-A2 in the media
were determined by a two-site ELISA (Laursen et al, 2007).
Assays for proteolytic activity
Purification of recombinant proteins (IGFBP-3, -4, and -5) was
carried out by affinity chromatography on a 1 ml HisTrap HP
column (GE Healthcare). Serum-free media were diluted 1:1 in
20 mM NaH2PO4, 150 mM NaCl, pH 7.4 (PBS) and loaded onto the
column with a flow rate of 1 ml/min. The column was washed with
20 column volumes of 50 mM NaH2PO4, 1 M NaCl, 20 mM imida-
zole, 0.05% Tween-20, pH 7.4, followed by five column volumes of
PBS. The proteins were eluted with 50 mM NaH2PO4, 300 mM
imidazole, pH 7.4, and dialyzed against 20 mM HEPES, 150 mM
NaCl, pH 7.4. Prior to iodination, the IGFBPs were further purified
by reversed-phase high-pressure liquid chromatography (RP-HPLC)
on a Discovery BIO Wide Pore C5 column (4 × 250 mm, Sigma), as
described (Gyrup & Oxvig, 2007). Protein purity was assessed by
SDS–PAGE, and quantification of purified proteins was done by
amino acid analysis. The purified IGFBPs were labeled with 125I
(Amersham Biosciences), and cleavage reactions were carried out as
previously described for PAPP-A (Winn et al, 2009). In brief, media
harvested from cells transfected with empty vector or human
PAPPA2 cDNA or variants thereof were diluted 1:25 and mixed with
125I-IGFBP-5 (10 nM) in 50 mM Tris–HCl, 100 mM NaCl, 1 mM
CaCl2, pH 7.5. For wild-type PAPP-A2, this dilution corresponds to a
concentration of 90 pM PAPP-A2 dimer. To assess activity toward
IGFBP-3 and -4, culture media were diluted 1:10, corresponding to a
PAPP-A2 concentration of 225 pM. Variants of all experiments in
which the IGFBPs were preincubated with IGF-I (100 nM; GroPep
Bioreagents) prior to the addition of PAPP-A2 were also carried out.
Following 3 h of incubation at 37°C, the reactions were terminated
by the addition of hot SDS–PAGE sample buffer supplemented with
25 mM EDTA. Substrate and cleavage products were separated by
nonreducing SDS–PAGE and visualized by autoradiography using a
storage phosphor screen (Molecular Dynamics) and a Typhoon
imaging system (GE Healthcare). To assess specific activity toward
the IGFBPs, cleavage reactions of 6 h were carried out using
equimolar concentrations of PAPP-A2 wild-type and mutant PAPP-
A2(A1033V).
Western blot analysis
Proteins separated by nonreducing or reducing SDS–PAGE were
blotted onto a PVDF membrane (Millipore), blocked with 2%
Tween-20, and equilibrated in 50 mM Tris–HCl, 500 mM NaCl,
0.1% Tween-20, pH 9.0 (TST). The blots were incubated overnight
at room temperature with an antiserum raised against the N-term-
inal laminin G-like module of PAPP-A2 diluted 1:10,000 in TST
containing 0.5% fetal bovine serum (Winn et al, 2009). The blots
were incubated for 1 h at room temperature with polyclonal swine
anti-rabbit IgG-HRP (DAKO, P0217) diluted 1:2,000 in TST contain-
ing 0.5% fetal bovine serum. All washing between the steps was
done with TST. The blots were developed using enhanced chemilu-
minescence (ECL Prime, GE Healthcare), and images were captured
and analyzed using an ImageQuant LAS 4000 instrument (GE
Healthcare). For quantification of mutant PAPP-A2 (A1033V), a
standard curve was generated based on serial dilutions of wild-type
PAPP-A2 of known concentration.
Pappa2 KO mice
All procedures involving mice complied with the standards stated in
the “Guide for the Care and Use of Laboratory Animals” and were
approved by the Institutional Animal Care and Use Committee of
Mayo Clinic.
Pappa2 KO mice are on a C57BL/6 background. They were
generated at Lexicon Pharmaceuticals Inc. (The Woodlands, TX).
Pappa2 KO and wild-type littermates were housed in a standard
pathogen-free mouse facility at Mayo Clinic with ad libitum access
to food and water. Serum total and free IGF-I were measured in
sixteen-week-old wild-type males (n = 9), wild-type females
(n = 12), KO males (n = 8), and KO females (n = 7).
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Micro-CT methods
Teeth were fixed in 4% paraformaldehyde and subjected to micro-
CT analyses (Skyscan 1172, at 70 kV, 9.75 lm per pixel, 0.4 in
degree rotation). Reconstruction of the raw images was performed
using NRecon V1.4.0 software (Skyscan).
Expanded View for this article is available online.
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